Prøve GULL - Gratis
Can India's National Medical Devices Policy Unleash Sector's Full Potential?
BioSpectrum Asia
|BioSpectrum Asia June 2023
The National Medical Devices Policy, 2023 that got the approval of the government of India on April 26 seems to have made the medical devices sector happy. The slew of strategies mentioned in the policy assures a win–win outcome for the manufacturers as well as patients. Experts are upbeat about the projected growth of the sector in the near future. The policy aims to bring a range of interventions in a coherent manner that would facilitate focussed and efficient support and facilitation for the sector by the respective agencies. Let’s explore further.
The medical devices sector was nothing short of thanking the government of India for the recently announced approved policy National Medical Devices Policy, 2023 by the Union Cabinet, chaired by the Prime Minister of India Narendra Modi. The policy is expected to help the medical devices sector to grow from present $11 billion to $50 billion in next five years. It is being touted by experts in the medical devices sector as a positive step where the industry is likely to become Atmanirbhar which will help to make affordable high quality and safe medical devices accessible to the world. This Policy will be in addition to the existing Production Linked Incentive (PLI) schemes that are underway.
Notably, till the recent 2023 Budget, the sector wasn’t all too pleased with the government’s position, as nothing substantial was announced for the sector. The sector had been seeking reforms since the past few years and ultimately it can now heave a sigh of relief.
Key focus areas
The current policy aims to put in place a comprehensive set of focus areas for the growth of the sector in a coordinated manner. The policy aims to bring a range of interventions in a coherent manner that would facilitate focussed and efficient support and facilitation for the sector by the respective agencies.
Denne historien er fra BioSpectrum Asia June 2023-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
Alphamab Oncology appoints Fei Wang as Chief Financial Officer
Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market
DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
PHCbi introduces LiCellGrow Cell Expansion System
PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences
CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala
Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation
Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Argo Biopharma ropes in Dr Gena Wang as CFO and CSO
China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust
The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Korea designs model for accurate and scalable drug-drug interaction prediction
A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.
1 min
BioSpectrum Asia April 2027
Translate
Change font size
